Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Apon Medical Technology Co., Ltd. (300753.SZ)
Nantong, CN
Jiangsu Apon Medical Technology Co., Ltd. operates within China, specializing in the development, manufacturing, and distribution of various medical devices. Its main offerings include microcomputer and disposable injection pumps, wireless analgesia management systems, and pulse oximeters. The company also supplies specific medical products like sensors tailored for pain management and sprayers designed for nasal care. Established in 2001, the firm's headquarters are situated in Nantong, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.79% | -11.64% | -18.48% | -35.33% | -16.49% | -19.86% | -12.44% | -2.46% | -11.25% | +52.54% | +52.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%-15.9% Q1'26: +5.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-321.7% Q1'26: +75.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-6.7% Q1'26: -38.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-11.1% Q1'26: -10.0% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-5.9% Q1'26: -2.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-9.74× Q1'26: -3.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
443.08M
est: 444.00M (-0.2%)
|
612.00M
est.
|
461.21M
est: 381.00M (+21.1%)
|
323.81M
est: 505.00M (-35.9%)
|
422.17M
est: 505.00M (-16.4%)
|
403.80M
est: 638.00M (-36.7%)
|
339.65M
est: 400.50M (-15.2%)
|
463.14M
463.14M – 463.14M
+15.6% YoY
|
532.54M
532.54M – 532.54M
+15.0% YoY
|
| EBITDA |
121.61M
est: 40.11M (+203.2%)
|
55.28M
est.
|
69.31M
est: 34.42M (+101.4%)
|
-74.48M
est: 45.62M (-263.3%)
|
29.55M
est: 45.62M (-35.2%)
|
38.50M
est: 6.26M (+514.8%)
|
-12.41M
est: 3.93M (-415.6%)
|
4.55M
4.55M – 4.55M
+15.6% YoY
|
5.23M
5.23M – 5.23M
+15.0% YoY
|
| EBIT |
111.91M
est: 18.98M (+489.7%)
|
26.16M
est.
|
56.53M
est: 16.29M (+247.1%)
|
-88.24M
est: 21.59M (-508.7%)
|
16.88M
est: 21.59M (-21.8%)
|
24.63M
est: -20.44M (+220.5%)
|
-37.78M
est: -12.83M (-194.5%)
|
-14.84M
-14.84M – -14.84M
-15.6% YoY
|
-17.06M
-17.06M – -17.06M
-15.0% YoY
|
| Net Income |
96.96M
est: 94.52M (+2.6%)
|
100.82M
est.
|
54.06M
est: 10.08M (+436.2%)
|
-75.98M
est: 59.23M (-228.3%)
|
8.28M
est: 59.23M (-86.0%)
|
10.80M
est: 108.40M (-90.0%)
|
-24.02M
|
2.52M
2.52M – 2.52M
|
5.04M
5.04M – 5.04M
+100.0% YoY
|
| SGA |
137.54M
est: 137.62M (-0.1%)
|
189.69M
est.
|
199.73M
est: 118.09M (+69.1%)
|
207.17M
est: 156.52M (+32.4%)
|
228.59M
est: 156.52M (+46.0%)
|
231.61M
est: 331.27M (-30.1%)
|
138.66M
est: 207.95M (-33.3%)
|
240.48M
240.48M – 240.48M
+15.6% YoY
|
276.51M
276.51M – 276.51M
+15.0% YoY
|
| EPS |
0.77
est: 0.75 (+2.7%)
|
0.80
est.
|
0.43
est: 0.08 (+437.5%)
|
-0.60
est: 0.47 (-227.7%)
|
0.07
est: 0.47 (-86.0%)
|
0.09
est: 0.86 (-90.0%)
|
-0.19
|
0.02
0.02 – 0.02
|
0.04
0.04 – 0.04
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongqi Yuan | Deputy GM & Chief Financial Officer | — | male |
| Haifeng Ying | Deputy General Manager | — | male |
| Yanfei Shi | Accounting Supervisor | — | — |
| Yu Fei Ye | Secretary to the Board | — | male |
| Zhi Hui Zhang | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300753.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
